Subcutaneous Cyclizine Dosing for Nausea in Adults
The standard subcutaneous dose of cyclizine for nausea in adults is 50 mg three times daily (150 mg/24 hours total), administered either as intermittent boluses or as a continuous subcutaneous infusion.
Dosing Recommendations
Based on real-world palliative care practice and pharmacokinetic data, cyclizine is commonly administered subcutaneously when oral routes are not feasible 1, 2:
- Standard dose: 50 mg SC three times daily (TDS)
- Alternative: 150 mg/24 hours via continuous subcutaneous infusion (CSCI)
- Frequency: The antihistaminic mechanism requires dosing 3-4 times daily for sustained effect
Pharmacokinetic Considerations
The pharmacokinetic profile supports this dosing strategy 1:
- Half-life: Median 13 hours (range 7-48 hours) in palliative care patients
- Time to steady state: Approximately 2-3 days with continuous infusion
- Volume of distribution: 23 L/kg, indicating extensive tissue distribution
- Clearance: 15 mL/min/kg
These parameters justify either intermittent dosing every 8 hours or continuous infusion to maintain therapeutic levels.
Clinical Effectiveness and Safety Profile
Recent prospective data from 101 palliative care patients demonstrates 2:
- Benefit rate: Approximately 75% of patients experience symptom improvement
- Harm rate: About one-third experience tolerable adverse effects
- Most common adverse effects: Constipation (13%), somnolence (9%), confusion (7%)
- Serious harms: Rare (4% with grade ≥3 events), typically exacerbations of pre-existing symptoms
Important caveat: Cyclizine is typically used in combination with other antiemetics rather than as monotherapy, particularly in palliative care settings where multifactorial nausea is common.
Administration Technique
For subcutaneous administration:
- Use standard subcutaneous sites (abdomen, thighs, upper arms)
- Rotate injection sites to minimize local irritation
- When using CSCI, cyclizine is compatible with most opioids and other palliative medications in syringe drivers
- Monitor injection sites for crystallization, particularly at higher concentrations
Clinical Context and Alternatives
Note the evidence limitations: The provided guidelines [3-4] focus primarily on chemotherapy-induced nausea and do not specifically address cyclizine, which is not a first-line agent in oncology settings. These guidelines recommend:
- First-line for chemotherapy: 5-HT3 antagonists, NK1 antagonists, and corticosteroids
- Dopamine antagonists (metoclopramide, prochlorperazine): 3-4 times daily dosing 3
Cyclizine's role is primarily in:
- Motion sickness and vestibular-mediated nausea
- Palliative care settings where oral routes are compromised
- Opioid-induced nausea (though not first-line per NCCN guidelines 5)
Monitoring and Adjustment
- Assess response at 72 hours: This is the typical timepoint for evaluating benefit versus harm 2
- Watch for anticholinergic effects: Particularly in elderly patients (dry mouth, urinary retention, confusion)
- Consider discontinuation if: No benefit by 72 hours or intolerable adverse effects develop
- Duration: In the palliative care cohort, 9% stopped at 72 hours and an additional 20% within 2 weeks, primarily due to symptom resolution or lack of benefit 2
Critical Safety Considerations
Contraindications and cautions:
- Avoid in patients with severe anticholinergic sensitivity
- Use cautiously in elderly patients due to increased confusion risk
- Monitor for exacerbation of pre-existing constipation, sedation, or delirium
- The metabolic pathway may involve CYP2D6, though clinical significance of genetic variation remains unclear 1